Brugada Syndrome;Síndrome de Brugada

Revista Espanola de Cardiologia

Volumn 62, Issue 11, 2009, Pages 1297-1315

  Benito, Begoña ^a   Brugada, Josep ^b   Brugada, Ramón ^c   Brugada, Pedro ^d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Channelopathies; Ions; Sudden death; Ventricular fibrillation

Indexed keywords

AJMALINE; ANGIOGENESIS INHIBITOR; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIHYDROQUINIDINE; FLECAINIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; ISOPRENALINE; NITRIC ACID DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PHOSPHODIESTERASE III INHIBITOR; PILSICAINIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACTION POTENTIAL; ALCOHOL INTOXICATION; AUTOSOMAL DOMINANT INHERITANCE; BRUGADA SYNDROME; CLINICAL FEATURE; DEFIBRILLATOR; DIAGNOSTIC ACCURACY; ELECTROCARDIOGRAM; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; QRS COMPLEX; REVIEW; SEX DIFFERENCE; ST SEGMENT; SYNCOPE;

BRUGADA SYNDROME; DECISION TREES; ELECTROCARDIOGRAPHY; HUMANS; PROGNOSIS; RISK ASSESSMENT;

EID: 72649101850     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)73082-9     Document Type: Review

References (81)

1. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
2. Proclemer A., Facchin D., Feruglio G.A., and Nucifora R. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report. G Ital Cardiol 23 (1993) 1211-1218
3. Ferracci A., Fromer M., Schlapfer J., Pruvot E., and Kappenberger L. Primary ventricular fibrillation and early recurrence: apropos of a case of association of right bundle branch block and persistent ST segment elevation. Arch Mal Coeur Vaiss 87 (1994) 1359-1362
4. Brugada P., Brugada R., and Brugada J. Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V1to V3and sudden death. Eur Heart J 21 (2000) 321-326
5. Priori S.G., Napolitano C., Gasparini M., Pappone C., La Bella C., Brignole M., et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 102 (2000) 2509-2515
6. Chen Q., Kirsch G.E., Zhang D., Brugada R., Brugada J., Brugada P., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 (1998) 293-296
7. Rook M.B., Bezzina Alshinawi C., Groenewegen W.A., Van Gelder I.C., Van Ginneken A.C., Jongsma H.J., et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res 44 (1999) 507-517
8. Yan G.X., and Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 (1999) 1660-1666
9. Wilde A.A.M., Antzelevitch C., Borggrefe M., Brugada J., Brugada R., Brugada P., et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 23 (2002) 1648-1654
10. Antzelevitch C., Brugada P., Borggrefe M., Brugada J., Brugada R., Corrado D., et al. Brugada syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111 (2005) 659-670
11. Van den Berg M.P., De Boer R.A., and Van Tintelen J.P. Brugada syndrome or Brugada electrocardiogram?. J Am Col Cardiol 53 (2009) 1569
12. Benito B., Brugada J., Brugada R., and Brugada P. Brugada syndrome or Brugada electrocardiogram? Authors' reply. J Am Coll Cardiol 53 (2009) 1569-1570
13. Hermida J.S., Lemoine J.L., Aoun F.B., Jarry G., Rey J.L., and Quiret J.C. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol 86 (2000) 91-94
14. Miyasaka Y., Tsuji H., Yamada K., Tokunaga S., Saito D., Imuro Y., et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 38 (2001) 771-774
15. Vatta M., Dumaine R., Varghese G., Richard T.A., Shimizu W., Aihara N., et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 11 (2002) 337-345
16. Benito B., Brugada R., Brugada J., and Brugada P. Brugada syndrome. Prog Cardiovasc Dis 51 (2008) 1-22
17. Vatta M., Dumaine R., Antzelevitch C., Brugada R., Li H., Bowles N.E., et al. Novel mutations in domain I of SCN5A cause Brugada syndrome. Mol Gen Metab 75 (2002) 317-324
18. Cordeiro J.M., Barajas-Martinez H., Hong K., Burashnikov E., Pfeiffer R., Orsino A.M., et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 114 (2006) 2026-2033
19. Casini S., Tan H.L., Bhuiyan Z.A., Bezzina C.R., Barnett P., Cerbai E., et al. Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation. Cardiovasc Res 76 (2007) 418-429
20. Pfahnl A.E., Viswanathan P.C., Weiss R., Shang L.L., Sanyal S., Shusterman V., et al. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm 4 (2007) 46-53
21. London B., Michalec M., Mehdi H., Kerchner L., Sanyal S., Viswanathan P.C., et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 116 (2007) 2260-2268
22. Weiss R., Barmada M.M., Nguyen T., Seibel J.S., Cavlovich D., Kornblit C.A., et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 105 (2002) 707-713
23. Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C., Aizawa Y., et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 115 (2007) 442-449
24. Delpon E., Cordeiro J.M., Nunez L., Thomsen P.E.B., Guerchicoff A., Pollevick G.D., et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 1 (2008) 209-218
25. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 29 (2006) 1130-1159
26. Shimizu W., Aiba T., and Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med 2 (2005) 408-414
27. Fish J., and Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 1 (2004) 210-217
28. Miyazaki T., Mitamura H., Miyoshi S., Soejima K., Aizawa Y., and Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 27 (1996) 1061-1070
29. Matsuo K., Kurita T., Inagaki M., Kakishita M., Aihara N., Shimizu W., et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 20 (1999) 465-470
30. Takigawa M., Noda T., Shimizu W., Miyamoto K., Okamura H., Satomi K., et al. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm 5 (2008) 1523-1527
31. Litovsky S.H., and Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res 67 (1990) 615-627
32. Benito B., Sarkozy A., Mont L., Henkens S., Berruezo A., Tamborero D., et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol 52 (2008) 1567-1573
33. Di Diego J.M., Cordeiro J.M., Goodrow R.J., Fish J.M., Zygmunt A.C., Pérez G.J., et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 106 (2002) 2004-2011
34. Brugada R., Brugada J., Antzelevitch C., Kirsch G.E., Potenza D., Towbin J.A., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101 (2000) 510-515
35. Belhassen B., Glick A., and Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110 (2004) 1731-1737
36. Ohgo T., Okamura H., Noda T., Satomi K., Suyama K., Kurita T., et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 4 (2007) 695-700
37. Brugada J., Brugada R., Antzelevitch C., Towbin J., Nademanee K., and Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 105 (2002) 73-78
38. Priori S.G., Napolitano C., Gasparini M., Pappone C., Bella P.D., Umberto G., et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105 (2002) 1342-1347
39. Brugada J., Brugada R., and Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108 (2003) 3092-3096
40. Eckardt L., Probst V., Smits J.P.P., Bahr E.S., Wolpert C., Schimpf R., et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 111 (2005) 257-263
41. Morita H., Kusano-Fukushima K., Nagase S., Fujimoto Y., Hisamatsu K., Fujio H., et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 40 (2002) 1437-1444
42. Benito B., and Brugada J. Recurrent syncope: an unusual presentation of Brugada syndrome. Nat Clin Pract Cardiovasc Med 3 (2006) 573-577
43. Makita N., Sumitomo N., Watanabe I., and Tsutsui H. Novel SCN5A mutation (Q55X) associated with age-dependent expression of Brugada syndrome presenting as neurally mediated syncope. Heart Rhythm 4 (2007) 516-519
44. Kies P., Wichter T., Schafers M., Schafers K.P., Eckardt L., Stegger L., et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome. Circulation 110 (2004) 3017-3022
45. Matsuo K., Akahoshi M., Seto S., and Yan K. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin Electrophysiol 26 (2003) 1551-1553
46. Shimizu W., Matsuo K., Kokubo Y., Satomi K., Kurita T., Noda T., et al. Sex hormone and gender difference-role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol 18 (2007) 415-421
47. Bai C.X., Kurokawa J., Tamagawa M., Nakaya H., and Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 112 (2005) 1701-1710
48. Song M., Helguera G., Eghbali M., Zhu N., Zarei M.M., Olcese R., et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem 276 (2001) 31883-31890
49. Probst V., Denjoy I., Meregalli P.G., Amirault J.C., Sacher F., Mansourati J., et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 115 (2007) 2042-2048
50. Benito B., Sarkozy A., Berne P., Brugada P., Brugada R., Partemi S., et al. Características clínicas y pronóstico del síndrome de Brugada en la población pediátrica. Rev Esp Cardiol 60 Supl 2 (2007) 70
51. Veltmann C., Schimpf R., Echternach C., Eckardt L., Kuschyk J., Streitner F., et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J 27 (2006) 2544-2552
52. Wilde A.A. Spontaneous electrocardiographic fluctuations in Brugada syndrome: does it matter?. Eur Heart J 27 (2006) 2493-2494
53. Dumaine R., Towbin J.A., Brugada P., Vatta M., Nesterenko D., Nesterenko V.V., et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 85 (1999) 803-809
54. González Rebollo J.M., Hernández M.A., García A., García de Castro A., Mejías A., and Moro C. Fibrilación ventricular recurrente durante un proceso febrilen un paciente con síndrome de Brugada. Rev Esp Cardiol 53 (2000) 755-757
55. Porres J.M., Brugada J., Urbistondo V., García F., Reviejo K., and Marco P. Fever unmasking the Brugada syndrome. Pacing Clin Electrophysiol 25 (2002) 1646-1648
56. Pitzalis M.V., Anaclerio M., Iacoviello M., Forleo C., Guida P., Troccoli R., et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 42 (2003) 1632-1637
57. Castro Hevia J., Antzelevitch C., Tornés Bárzaga F., Dorantes Sánchez M., Dorticos Balea F., Zayas Molina R., et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 47 (2006) 1828-1834
58. Babai Bigi M.A., Aslani A., and Shahrzad S. aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm 4 (2007) 1009-1012
59. Fish J.M., and Antzelevitch C. Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol 19 (2008) 301-308
60. Tada T., Kusano K.F., Nagase S., Banba K., Miura D., Nishii N., et al. The relationship between the magnitude of T wave alternans and amplitude of the corresponding T wave in patients with Brugada syndrome. J Cardiovasc Electrophysiol 19 (2008) 56-61
61. Sarkozy A., Chierchia G.B., Paparella G., Boussy T., De Asmundis C., Roos M., et al. Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. Circ Arrhythmia Electrophysiol 2 (2009) 154-161
62. Kyndt F., Probst V., Potet F., Demolombe S., Chevallier J.C., Baro I., et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 104 (2001) 3081-3086
63. Smits J.P., Eckardt L., Probst V., Bezzina C.R., Schott J.J., Remme C.A., et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 40 (2002) 350-356
64. Junttila M.J., Brugada P., Hong K., Lizotte E., De Zutter M., Sarkozy A., et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 19 (2007) 380-383
65. Fish J.M., and Antzelevitch C. Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. J Electrocardiol 36 Suppl (2003) 173-179
66. Hong K., Brugada J., Oliva A., Berruezo-Sánchez A., Potenza D., Pollevick G.D., et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 110 (2004) 3023-3027
67. Meregalli P.G., Ruijter J.M., Hofman N., Bezzina C.R., Wilde A.A., and Tan H.L. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 17 (2006) 857-864
68. Wolpert C., Echternach C., Veltmann C., Antzelevitch C., Thomas G.P., Spehl S., et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2 (2005) 254-260
69. Sangwatanaroj S., Prechawat S., Sunsaneewitayakul B., Sitthisook S., Tosukhowong P., and Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 22 (2001) 2290-2296
70. Miyamoto K., Yokokawa M., Tanaka K., Nagai T., Okamura H., Noda T., et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 99 (2007) 53-57
71. Brugada P., Brugada R., Brugada J., Priori S., and Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. Circulation 112 (2005) 279-292
72. Kusano K.F., Taniyama M., Nakamura K., Miura D., Banba K., Nagase S., et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 51 (2008) 1169-1175
73. Meregalli P.G., Tan H.L., Probst V., Koopmann T.T., Tanck M.W., Bhuiyan Z.A., et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 6 (2009) 341-348
74. Benito B., Campuzano O., Ishac R., Iglesias A., Junttila M.J., Michaud J., et al. Role of genetic testing in risk stratification of Brugada syndrome. Heart Rhythm 6 (2009) S102
75. Lizotte E, Junttila MJ, Dube MP, Hong K, Benito B, De Zutter M, et al. Genetic modulation of Brugada syndrome by a common polymorphism. J Cardiovasc Electrophysiol. 2009 Jun 22 [Epub ahead of print].
76. Sacher F., Probst V., Iesaka Y., Jacon P., Laborderie J., Mizon-Gerard F., et al. Outcome after implantation of a cardioverterdefibrillator in patients with Brugada syndrome: a multicenter study. Circulation 114 (2006) 2317-2324
77. Sarkozy A., Boussy T., Kourgiannides G., Chierchia G.B., Richter S., De Potter T., et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 28 (2007) 334-344
78. Maron B.J., Shen W.K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
79. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
80. Mok N.S., Chan N.Y., and Chiu A.C. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 27 (2004) 821-823
81. Hermida J.S., Denjoy I., Clerc J., Extramiana F., Jarry G., Milliez P., et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 43 (2004) 1853-1860